Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A randomised Phase III trial to evaluate the efficacy of chemoimmunotherapy with the monoclonal antibody Campath-1H (Alemtuzumab) given in combination with 2-weekly CHOP (Cyclophosphamide, Doxorubicin, Vincristine and Prednisone) versus 2-weekly CHOP alone in elderly patients with previously untreated systemic T- cell Lymphoma Short Title: A-CHOP-14 (elderly)

Next Previous
Search
Trial Profile

A randomised Phase III trial to evaluate the efficacy of chemoimmunotherapy with the monoclonal antibody Campath-1H (Alemtuzumab) given in combination with 2-weekly CHOP (Cyclophosphamide, Doxorubicin, Vincristine and Prednisone) versus 2-weekly CHOP alone in elderly patients with previously untreated systemic T- cell Lymphoma Short Title: A-CHOP-14 (elderly)

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 29 Jan 2021

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Alemtuzumab (Primary) ; Cyclophosphamide; Doxorubicin; Granulocyte colony-stimulating factors; Prednisone; Vincristine
  • Indications Anaplastic large cell lymphoma; Carcinoma; Extranodal NK-T-cell lymphoma; Hodgkin's disease; Non-Hodgkin's lymphoma; Peripheral T-cell lymphoma; T-cell lymphoma
  • Focus Therapeutic Use
  • Acronyms A-CHOP-14; HOVON 91 T-NHL / ACT-2

Most Recent Events

  • 01 Jan 2021 Primary endpoint has not been met. (Event free survival)
  • 01 Jan 2021 Results published in the Leukemia
  • 04 Dec 2018 Results (n=252) of pooled analysis of ACT-1 and ACT-2 comparing CHOP with A-CHOP to increase statistical power, presented at the 60th Annual Meeting and Exposition of the American Society of Hematology.

You need to be a logged in or subscribed to view this content Request demo (opens in a new window)

If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top